{"id":6538,"date":"2025-10-30T16:06:11","date_gmt":"2025-10-30T20:06:11","guid":{"rendered":"https:\/\/doctorgmed.com\/?p=4982"},"modified":"2025-10-30T16:06:11","modified_gmt":"2025-10-30T20:06:11","slug":"tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular","status":"publish","type":"post","link":"https:\/\/doctorgmed.com\/en\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/","title":{"rendered":"Tirzepatide: Dual agonist that reduces sweat apnea, fat liver and cardiovascular risk"},"content":{"rendered":"<h1><b><i>Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular<\/i><\/b><\/h1>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, su uso est\u00e1 autorizado para el tratamiento de la diabetes tipo 2 y el control de peso (obesidad o sobrepeso con comorbilidades), y la evidencia cl\u00ednica lo consolida como un agente sist\u00e9mico que reduce significativamente el riesgo de m\u00faltiples complicaciones graves, incluyendo la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ol>\n<li><span style=\"font-weight: 400;\"> Mecanismo Dual: La Clave de la Eficacia Sist\u00e9mica<\/span><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">La Tirzepatida act\u00faa sobre dos hormonas intestinales (incretinas) clave, lo que proporciona una respuesta metab\u00f3lica m\u00e1s potente que los tratamientos de acci\u00f3n simple.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Acci\u00f3n GLP-1 (P\u00e9ptido similar al Glucag\u00f3n-1): \u00a0 Aumenta la secreci\u00f3n de insulina (reduciendo la glucosa), suprime la liberaci\u00f3n de glucag\u00f3n y, crucialmente, act\u00faa a nivel cerebral para \u00a0 incrementar la saciedad \u00a0 y \u00a0 reducir el apetito\u00a0 .<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Acci\u00f3n GIP (Polip\u00e9ptido Inhibitorio G\u00e1strico): \u00a0 Mejora la \u00a0 sensibilidad a la insulina \u00a0 y se ha observado que potencia los efectos del GLP-1. Esta acci\u00f3n dual resulta en una \u00a0 p\u00e9rdida de peso superior \u00a0 (con reducciones de peso promedio que superan el 20% en algunos estudios) y un control gluc\u00e9mico m\u00e1s robusto.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ol start=\"2\">\n<li><span style=\"font-weight: 400;\"> Beneficios Estructurales y Respiratorios<\/span><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">La Tirzepatida ha demostrado ser un tratamiento que va a la ra\u00edz de las comorbilidades.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ol>\n<li><span style=\"font-weight: 400;\"> Reducci\u00f3n de la Apnea del Sue\u00f1o (SAOS)\u00a0\u00a0<\/span><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Evidencia Cl\u00ednica (Estudio SURMOUNT-OSA): \u00a0 Los ensayos cl\u00ednicos han demostrado que la Tirzepatida es altamente eficaz en la reducci\u00f3n de la gravedad del \u00a0 S\u00edndrome de Apnea Obstructiva del Sue\u00f1o (SAOS) \u00a0 en pacientes con obesidad.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Resultados: \u00a0 El f\u00e1rmaco reduce dr\u00e1sticamente el \u00a0 \u00cdndice de Apnea-Hipopnea (IAH) \u00a0 (el n\u00famero de interrupciones respiratorias por hora).<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Impacto: \u00a0 Esto convierte la Tirzepatida en una \u00a0 opci\u00f3n farmacol\u00f3gica pionera \u00a0 para tratar la patolog\u00eda subyacente del SAOS (la obesidad y el exceso de tejido blando en las v\u00edas a\u00e9reas superiores), algo que tradicionalmente se manejaba solo con CPAP o cirug\u00eda.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ol>\n<li><span style=\"font-weight: 400;\"> H\u00edgado Graso (Esteatosis Hep\u00e1tica \/ MASH)\u00a0\u00a0<\/span><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Efecto: \u00a0 La Tirzepatida ha mostrado beneficios significativos en la resoluci\u00f3n de la \u00a0 Esteato-Hepatitis Asociada a Disfunci\u00f3n Metab\u00f3lica (MASH)\u00a0 , una enfermedad hep\u00e1tica progresiva ligada a la obesidad y la resistencia a la insulina.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Mecanismo: \u00a0 La reducci\u00f3n potente del peso corporal y la mejora de la sensibilidad a la insulina contribuyen a disminuir la acumulaci\u00f3n de grasa y la inflamaci\u00f3n en el h\u00edgado, revirtiendo el da\u00f1o hep\u00e1tico.<\/span><\/p>\n<p>&nbsp;<\/p>\n<ol start=\"3\">\n<li><span style=\"font-weight: 400;\"> Reducci\u00f3n del Riesgo Cardiovascular y Renal<\/span><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">Los efectos sist\u00e9micos de la Tirzepatida se extienden a la protecci\u00f3n de \u00f3rganos vitales.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Insuficiencia Card\u00edaca (IC): \u00a0 Estudios (como el SUMMIT) en pacientes con obesidad e Insuficiencia Card\u00edaca con fracci\u00f3n de eyecci\u00f3n preservada (ICFEp) han mostrado que el tratamiento con Tirzepatida puede \u00a0 reducir la incidencia de empeoramiento de la IC \u00a0 y mejorar la funcionalidad y tolerancia al ejercicio.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Protecci\u00f3n Renal: \u00a0 En pacientes con diabetes tipo 2 y alto riesgo cardiovascular, la Tirzepatida ha demostrado \u00a0 ralentizar el ritmo de disminuci\u00f3n de la funci\u00f3n renal \u00a0 y mejorar marcadores renales clave (como la albuminuria), ofreciendo protecci\u00f3n contra la progresi\u00f3n de la enfermedad renal cr\u00f3nica.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0\u00a0\u00a0Marcadores de Riesgo: \u00a0 Adem\u00e1s de la reducci\u00f3n de peso, se observan mejoras en los factores de riesgo metab\u00f3lico, como la disminuci\u00f3n de los niveles de \u00a0 presi\u00f3n arterial\u00a0 , el perfil lip\u00eddico (colesterol y triglic\u00e9ridos) y la reducci\u00f3n de la \u00a0 inflamaci\u00f3n sist\u00e9mica \u00a0 (medida por la PCR-as).<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">\u00a0\u00a0Conclusi\u00f3n: \u00a0 La Tirzepatida (Mounjaro), al actuar como agonista dual, ofrece un tratamiento integral que aborda la obesidad no solo como un problema de peso, sino como una \u00a0 enfermedad multisist\u00e9mica\u00a0 . Su capacidad para mejorar el sue\u00f1o, la salud hep\u00e1tica y el riesgo cardiovascular la convierte en una terapia de referencia en la endocrinolog\u00eda y cardiolog\u00eda modernas en Espa\u00f1a. Su uso siempre debe ser guiado y supervisado por un m\u00e9dico especialista.<\/span><\/p>\n<figure id=\"attachment_4983\" aria-describedby=\"caption-attachment-4983\" style=\"width: 1198px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/doctorgmed.com\/es\/\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-4983\" title=\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular\" src=\"https:\/\/doctorgmed.com\/wp-content\/uploads\/2025\/10\/Tirzepatida-El-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular02-300x123.png\" alt=\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular\" width=\"1198\" height=\"491\" \/><\/a><figcaption id=\"caption-attachment-4983\" class=\"wp-caption-text\"><\/strong><\/em> <em><strong><a href=\"https:\/\/doctorgmed.com\/es\/\">Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular<\/a><\/strong><\/em><\/figcaption><\/figure>\n<h1><b><i>Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular<\/i><\/b><\/h1>\n<div id=\"map_canvas\" class=\"wpseo-map-canvas\" style=\"max-width: 100%; width: 400px; height: 300px;\"><ul><li><a href=\"https:\/\/doctorgmed.com\/\">Doctor G Medical Excellence: Health Well-being and Longevity<\/a><\/li><\/ul><\/div><div id=\"wpseo-directions-wrapper\"><h3 id=\"wpseo-directions\" class=\"wpseo-directions-heading\">Route<\/h3><form action=\"\" method=\"post\" class=\"wpseo-directions-form\" id=\"wpseo-directions-form\" onsubmit=\"wpseo_calculate_route( wpseoMapOptions[0].map, wpseoMapOptions[0].directionsDisplay, wpseoMapOptions[0].mapVars[0], wpseoMapOptions[0].mapVars[1], 0); return false;\"><p>Your location: <input type=\"text\" size=\"20\" id=\"origin\" value=\"\" \/><input type=\"submit\" class=\"wpseo-directions-submit\" value=\"Show route\"><span id=\"wpseo-noroute\" style=\"display: none;\">No route could be calculated.<\/span><\/p><\/form><div id=\"directions\"><\/div><\/div>\n<div id=\"wpseo_location-\" class=\"wpseo-location\"><h3><span class=\"wpseo-business-name\">Doctor G Medical Excellence: Health Well-being and Longevity<\/span><\/h3><div class=\"wpseo-address-wrapper\"><div class=\"street-address\">4243 W Hillsboro blvd<\/div><span class=\"locality\"> Coconut Creek<\/span>, <span  class=\"region\">Florida<\/span> <span class=\"postal-code\">33073<\/span> <div  class=\"country-name\">United States (US)<\/div><\/div><span class=\"wpseo-phone\">Phone: <a href=\"tel:+19546381515\" class=\"tel\"><span>+1 (954) 638-1515<\/span><\/a><\/span><br\/><span class=\"wpseo-email\">Email: <a href=\"mailto:dr&#103;&#109;&#101;&#100;&#064;d&#111;&#099;t&#111;&#114;bgmed&#046;com\">&#100;r&#103;m&#101;d&#64;&#100;o&#99;tor&#98;gm&#101;d.c&#111;&#109;<\/a><\/span><br\/><span class=\"wpseo-url\">URL: <a href=\"https:\/\/doctorgmed.com\/\">https:\/\/doctorgmed.com\/<\/a><\/span><br\/><\/div>\n<div class=\"wpseo-opening-hours-wrapper\"><table class=\"wpseo-opening-hours\" id =\"wpseo-opening-hours-\"><tr><td class=\"day\">Monday<\/td><td class=\"time\"><span>09:00 - 17:00<\/span><\/td><\/tr><tr><td class=\"day\">Tuesday<\/td><td class=\"time\"><span>09:00 - 17:00<\/span><\/td><\/tr><tr><td class=\"day\">Wednesday<\/td><td class=\"time\"><span>09:00 - 17:00<\/span><\/td><\/tr><tr><td class=\"day\">Thursday<\/td><td class=\"time\"><span>09:00 - 17:00<\/span><\/td><\/tr><tr><td class=\"day\">Friday<\/td><td class=\"time\"><span>09:00 - 17:00<\/span><\/td><\/tr><tr><td class=\"day\">Saturday<\/td><td class=\"time\"><span>09:00 - 17:00<\/span><\/td><\/tr><tr><td class=\"day\">Sunday<\/td><td class=\"time\">Closed<\/td><\/tr><\/table><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular &nbsp; El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4984,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1122],"tags":[1123,1124],"class_list":["post-6538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-el-higado-graso-y-el-riesgo-cardiovascular","tag-el-higado-graso-y-el-riesgo-cardiovascular","tag-tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular<\/title>\n<meta name=\"description\" content=\"El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, su uso est\u00e1 autorizado para el tratamiento de la diabetes tipo 2 y el control de peso (obesidad o sobrepeso con comorbilidades), y la evidencia cl\u00ednica lo consolida como un agente sist\u00e9mico que reduce significativamente el riesgo de m\u00faltiples complicaciones graves, incluyendo la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/doctorgmed.com\/en\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular\" \/>\n<meta property=\"og:description\" content=\"El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, su uso est\u00e1 autorizado para el tratamiento de la diabetes tipo 2 y el control de peso (obesidad o sobrepeso con comorbilidades), y la evidencia cl\u00ednica lo consolida como un agente sist\u00e9mico que reduce significativamente el riesgo de m\u00faltiples complicaciones graves, incluyendo la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/doctorgmed.com\/en\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/\" \/>\n<meta property=\"og:site_name\" content=\"Doctor G Medical Excellence: Health Well-being and Longevity\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T20:06:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/doctorgmed.com\/wp-content\/uploads\/2025\/08\/logo_bgmed_black.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"rz_dn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular\" \/>\n<meta name=\"twitter:description\" content=\"El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, su uso est\u00e1 autorizado para el tratamiento de la diabetes tipo 2 y el control de peso (obesidad o sobrepeso con comorbilidades), y la evidencia cl\u00ednica lo consolida como un agente sist\u00e9mico que reduce significativamente el riesgo de m\u00faltiples complicaciones graves, incluyendo la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular.\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rz_dn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/\"},\"author\":{\"name\":\"rz_dn\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/#\\\/schema\\\/person\\\/185b73e2ad9162453b5fd5cd9177153b\"},\"headline\":\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular\",\"datePublished\":\"2025-10-30T20:06:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/\"},\"wordCount\":834,\"publisher\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"el h\u00edgado graso y el riesgo cardiovascular\",\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o\"],\"articleSection\":[\"el h\u00edgado graso y el riesgo cardiovascular\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/en\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/\",\"url\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/\",\"name\":\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2025-10-30T20:06:11+00:00\",\"description\":\"El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, su uso est\u00e1 autorizado para el tratamiento de la diabetes tipo 2 y el control de peso (obesidad o sobrepeso con comorbilidades), y la evidencia cl\u00ednica lo consolida como un agente sist\u00e9mico que reduce significativamente el riesgo de m\u00faltiples complicaciones graves, incluyendo la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/doctorgmed.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/#website\",\"url\":\"https:\\\/\\\/doctorgmed.com\\\/\",\"name\":\"Doctor G Medical Excellence: Health Well-being and Longevity\",\"description\":\"Doctor G Medical Excellence | 4243 W Hillsboro blvd Coconut Creek, 33073, FL United States \ud83d\udcde  +1 (954) 638-1515\",\"publisher\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/#organization\"},\"alternateName\":\"Doctor G Medical Excellence: Health Well-being and Longevity\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/doctorgmed.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Organization\",\"Place\",\"MedicalClinic\"],\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/#organization\",\"name\":\"Doctor G Medical Excellence: Health Well-being and Longevity\",\"alternateName\":\"Doctor G Medical Excellence: Health Well-being and Longevity\",\"url\":\"https:\\\/\\\/doctorgmed.com\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#local-main-organization-logo\"},\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/p\\\/DGUBdcpxKmB\\\/\"],\"description\":\"Doctor G Medical Excellence | 4243 W Hillsboro blvd Coconut Creek, 33073, FL United States \ud83d\udcde +1 (954) 638-1515\",\"foundingDate\":\"2000-02-24\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"201\",\"maxValue\":\"500\"},\"publishingPrinciples\":\"https:\\\/\\\/doctorgmed.com\\\/contato\\\/\",\"ownershipFundingInfo\":\"https:\\\/\\\/doctorgmed.com\\\/contato\\\/\",\"actionableFeedbackPolicy\":\"https:\\\/\\\/doctorgmed.com\\\/contato\\\/\",\"correctionsPolicy\":\"https:\\\/\\\/doctorgmed.com\\\/contato\\\/\",\"ethicsPolicy\":\"https:\\\/\\\/doctorgmed.com\\\/contato\\\/\",\"diversityPolicy\":\"https:\\\/\\\/doctorgmed.com\\\/contato\\\/\",\"diversityStaffingReport\":\"https:\\\/\\\/doctorgmed.com\\\/contato\\\/\",\"address\":{\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#local-main-place-address\"},\"geo\":{\"@type\":\"GeoCoordinates\",\"latitude\":\"26.318806\",\"longitude\":\"-80.1835615\"},\"telephone\":[\"+1 (954) 638-1515\"],\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\",\"Saturday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"},{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Sunday\"],\"opens\":\"00:00\",\"closes\":\"00:00\"}],\"email\":\"drgmed@doctorbgmed.com\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/#\\\/schema\\\/person\\\/185b73e2ad9162453b5fd5cd9177153b\",\"name\":\"rz_dn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/01bb50b0f72cc6ef33117044fc730d8353cdadefc3bf1ebde0f113f548530d1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/01bb50b0f72cc6ef33117044fc730d8353cdadefc3bf1ebde0f113f548530d1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/01bb50b0f72cc6ef33117044fc730d8353cdadefc3bf1ebde0f113f548530d1c?s=96&d=mm&r=g\",\"caption\":\"rz_dn\"},\"sameAs\":[\"https:\\\/\\\/drbgmed.raszio.com\"],\"url\":\"https:\\\/\\\/doctorgmed.com\\\/en\\\/author\\\/rz_dn\\\/\"},{\"@type\":\"PostalAddress\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#local-main-place-address\",\"streetAddress\":\"4243 W Hillsboro blvd\",\"addressLocality\":\"Coconut Creek\",\"postalCode\":\"33073\",\"addressRegion\":\"Florida\",\"addressCountry\":\"US\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/doctorgmed.com\\\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/doctorgmed.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo_bgmed_black.png\",\"contentUrl\":\"https:\\\/\\\/doctorgmed.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo_bgmed_black.png\",\"width\":1080,\"height\":1080,\"caption\":\"Doctor G Medical Excellence: Health Well-being and Longevity\"}]}<\/script>\n<meta name=\"geo.placename\" content=\"Coconut Creek\" \/>\n<meta name=\"geo.position\" content=\"26.318806;-80.1835615\" \/>\n<meta name=\"geo.region\" content=\"United States (US)\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tirzepatide: Dual agonist that reduces sweat apnea, fat liver and cardiovascular risk","description":"The drug Mounjaro (active ingredient: Tirzepatide) has revolutionized metabolic medicine thanks to its innovative mechanism as a dual agonist of the GIP and GLP-1 receptors. In Spain, its use is authorized for the treatment of type 2 diabetes and weight control (obesity or overweight with comorbidities), and clinical evidence consolidates it as a systemic agent that significantly reduces the risk of multiple serious complications, including sweat apnea, fatty liver and cardiovascular risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/doctorgmed.com\/en\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/","og_locale":"en_US","og_type":"article","og_title":"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular","og_description":"El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, su uso est\u00e1 autorizado para el tratamiento de la diabetes tipo 2 y el control de peso (obesidad o sobrepeso con comorbilidades), y la evidencia cl\u00ednica lo consolida como un agente sist\u00e9mico que reduce significativamente el riesgo de m\u00faltiples complicaciones graves, incluyendo la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular.","og_url":"https:\/\/doctorgmed.com\/en\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/","og_site_name":"Doctor G Medical Excellence: Health Well-being and Longevity","article_published_time":"2025-10-30T20:06:11+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/doctorgmed.com\/wp-content\/uploads\/2025\/08\/logo_bgmed_black.png","type":"image\/png"}],"author":"rz_dn","twitter_card":"summary_large_image","twitter_title":"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular","twitter_description":"El medicamento \u00a0 Mounjaro \u00a0 (principio activo: \u00a0 Tirzepatida\u00a0 ) ha revolucionado la medicina metab\u00f3lica gracias a su innovador mecanismo como \u00a0 agonista dual \u00a0 de los receptores \u00a0 GIP \u00a0 y \u00a0 GLP-1\u00a0 . En Espa\u00f1a, su uso est\u00e1 autorizado para el tratamiento de la diabetes tipo 2 y el control de peso (obesidad o sobrepeso con comorbilidades), y la evidencia cl\u00ednica lo consolida como un agente sist\u00e9mico que reduce significativamente el riesgo de m\u00faltiples complicaciones graves, incluyendo la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular.","twitter_misc":{"Written by":"rz_dn","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#article","isPartOf":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/"},"author":{"name":"rz_dn","@id":"https:\/\/doctorgmed.com\/#\/schema\/person\/185b73e2ad9162453b5fd5cd9177153b"},"headline":"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular","datePublished":"2025-10-30T20:06:11+00:00","mainEntityOfPage":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/"},"wordCount":834,"publisher":{"@id":"https:\/\/doctorgmed.com\/#organization"},"image":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#primaryimage"},"thumbnailUrl":"","keywords":["el h\u00edgado graso y el riesgo cardiovascular","Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o"],"articleSection":["el h\u00edgado graso y el riesgo cardiovascular"],"inLanguage":"en-US","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/doctorgmed.com\/en\/#organization"}},{"@type":"WebPage","@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/","url":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/","name":"Tirzepatide: Dual agonist that reduces sweat apnea, fat liver and cardiovascular risk","isPartOf":{"@id":"https:\/\/doctorgmed.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#primaryimage"},"image":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#primaryimage"},"thumbnailUrl":"","datePublished":"2025-10-30T20:06:11+00:00","description":"The drug Mounjaro (active ingredient: Tirzepatide) has revolutionized metabolic medicine thanks to its innovative mechanism as a dual agonist of the GIP and GLP-1 receptors. In Spain, its use is authorized for the treatment of type 2 diabetes and weight control (obesity or overweight with comorbidities), and clinical evidence consolidates it as a systemic agent that significantly reduces the risk of multiple serious complications, including sweat apnea, fatty liver and cardiovascular risk.","breadcrumb":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/doctorgmed.com\/"},{"@type":"ListItem","position":2,"name":"Tirzepatida: El agonista dual que reduce la apnea del sue\u00f1o, el h\u00edgado graso y el riesgo cardiovascular"}]},{"@type":"WebSite","@id":"https:\/\/doctorgmed.com\/#website","url":"https:\/\/doctorgmed.com\/","name":"Doctor G Medical Excellence: Health Well-being and Longevity","description":"Doctor G Medical Excellence | 4243 W Hillsboro blvd Coconut Creek, 33073, FL United States \ud83d\udcde +1 (954) 638-1515","publisher":{"@id":"https:\/\/doctorgmed.com\/#organization"},"alternateName":"Doctor G Medical Excellence: Health Well-being and Longevity","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/doctorgmed.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Organization","Place","MedicalClinic"],"@id":"https:\/\/doctorgmed.com\/#organization","name":"Doctor G Medical Excellence: Health Well-being and Longevity","alternateName":"Doctor G Medical Excellence: Health Well-being and Longevity","url":"https:\/\/doctorgmed.com\/","logo":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#local-main-organization-logo"},"image":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#local-main-organization-logo"},"sameAs":["https:\/\/www.instagram.com\/p\/DGUBdcpxKmB\/"],"description":"Doctor G Medical Excellence | 4243 W Hillsboro blvd Coconut Creek, 33073, FL United States \ud83d\udcde +1 (954) 638-1515","foundingDate":"2000-02-24","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"201","maxValue":"500"},"publishingPrinciples":"https:\/\/doctorgmed.com\/contato\/","ownershipFundingInfo":"https:\/\/doctorgmed.com\/contato\/","actionableFeedbackPolicy":"https:\/\/doctorgmed.com\/contato\/","correctionsPolicy":"https:\/\/doctorgmed.com\/contato\/","ethicsPolicy":"https:\/\/doctorgmed.com\/contato\/","diversityPolicy":"https:\/\/doctorgmed.com\/contato\/","diversityStaffingReport":"https:\/\/doctorgmed.com\/contato\/","address":{"@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#local-main-place-address"},"geo":{"@type":"GeoCoordinates","latitude":"26.318806","longitude":"-80.1835615"},"telephone":["+1 (954) 638-1515"],"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"opens":"09:00","closes":"17:00"},{"@type":"OpeningHoursSpecification","dayOfWeek":["Sunday"],"opens":"00:00","closes":"00:00"}],"email":"drgmed@doctorbgmed.com"},{"@type":"Person","@id":"https:\/\/doctorgmed.com\/#\/schema\/person\/185b73e2ad9162453b5fd5cd9177153b","name":"rz_dn","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/01bb50b0f72cc6ef33117044fc730d8353cdadefc3bf1ebde0f113f548530d1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/01bb50b0f72cc6ef33117044fc730d8353cdadefc3bf1ebde0f113f548530d1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/01bb50b0f72cc6ef33117044fc730d8353cdadefc3bf1ebde0f113f548530d1c?s=96&d=mm&r=g","caption":"rz_dn"},"sameAs":["https:\/\/drbgmed.raszio.com"],"url":"https:\/\/doctorgmed.com\/en\/author\/rz_dn\/"},{"@type":"PostalAddress","@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#local-main-place-address","streetAddress":"4243 W Hillsboro blvd","addressLocality":"Coconut Creek","postalCode":"33073","addressRegion":"Florida","addressCountry":"US"},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/doctorgmed.com\/tirzepatida-el-agonista-dual-que-reduce-la-apnea-del-sueno-el-higado-graso-y-el-riesgo-cardiovascular\/#local-main-organization-logo","url":"https:\/\/doctorgmed.com\/wp-content\/uploads\/2025\/08\/logo_bgmed_black.png","contentUrl":"https:\/\/doctorgmed.com\/wp-content\/uploads\/2025\/08\/logo_bgmed_black.png","width":1080,"height":1080,"caption":"Doctor G Medical Excellence: Health Well-being and Longevity"}]},"geo.placename":"Coconut Creek","geo.position":{"lat":"26.318806","long":"-80.1835615"},"geo.region":"United States (US)"},"_links":{"self":[{"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/posts\/6538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/comments?post=6538"}],"version-history":[{"count":0,"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/posts\/6538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/doctorgmed.com\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/media?parent=6538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/categories?post=6538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/doctorgmed.com\/en\/wp-json\/wp\/v2\/tags?post=6538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}